Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 18, Issue 5, 2008, Pages 1071-1078

  Jobsen, J J ^a   Lybeert, M L M ^b   Van Der Steen Banasik, E M ^c   Slot, A ^d   Van Der Palen, J ^a   Ten Cate, L N ^e   Scholten, A ^f   Coen, V ^g   Schutter, E M J ^a   Siesling, S ^h  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c Arnhems Radiotherapeutisch Instituut   (Netherlands)

^d Radiotherapy Institute Friesland   (Netherlands)

^e Laboratorium Pathologie Oost Nederland   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Zeeuws Radiotherapy Institute   (Netherlands)

^h Integraal Kankercentrum Stedendriehoek Twente   (Netherlands)

Author keywords

Endometrial carcinoma; Outcome; Prognostic factors; Stage II

Indexed keywords

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 51749103754     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01142.x     Document Type: Article

References (23)

1. Visser O, Coebergh JWW, Schouten LJ, van Dijk JAAM. Incidence of cancer in the Netherlands 1995. Utrecht, The Netherlands : Netherlands Cancer Registry, 1998.
2. Crasman WT. Announcement: FIGO stages - 1988 revision. Gynecol Oncol 1989 35 : 125 7.
3. Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. Gynecol Oncol 1999 74 : 350 5.
4. Creutzberg CL, van Putten WLJ, Koper PCM et al. Randomized trial of surgery and postoperative radiation therapy versus surgery alone for patients with stage I endometrial carcinoma. Lancet 2000 355 : 1404 11.
5. Look K. Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation. Int J Gynecol Cancer 2002 12 : 237 49.
6. Pitson G, Colgan T, Levin W et al. Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys 2002 53 : 862 7.
7. Sartori E, Gadducci A, Landoni F et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and adjuvant radiation therapy. Int J Gynecol Cancer 2001 11 : 430 7.
8. Morrow CP, Bundy BN, Kurman RJ et al. Relationship between surgical pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: gynecologic Oncology Group study. Gynecol Oncol 1991 40 : 55 65.
9. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications of therapy. Obstet Gynecol 1992 80 : 655 9.
10. Boente MP, Yordan EL, McIntosh DG et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1993 51 : 316 22.
11. Jobsen JJ, Schutter EMJ, Meerwaldt JH et al. Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma. Int J Gynecol Cancer 2001 11 : 49 53.
12. Descamps P, Calais G, Moire C et al. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol 1997 64 : 54 8.
13. Watari H, Todo Y, Takeda M et al. Lymphvascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol 2005 96 : 651 7.
14. Briet JM, Hollema H, Reesink N et al. Lymph vascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 2005 96 : 799 804.
15. Mariani A, Keeney GL, Aletti G et al. Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol 2004 92 : 833 8.
16. Cohn DE, Horowitz NS, Mutch DG et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? Gynecol Oncol 2002 87 : 243 6.
17. Inou EY, Obata K, Abe K et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 1996 78 : 1447 51.
18. Honore LH, Hanson J. Statistical analysis of pathologic risk factors for intramyometrial lymphvascular space involvement in myoinvasive endometrial carcinoma. Int J Gynecol Cancer 2006 16 : 1330 5.
19. Meerwaldt JH, Hoekstra CJM, van Putten WLJ et al. Endometrial adenocarcinoma, adjuvant radiotherapy tailored to prognostic factors. Int J Radiat Oncol Biol Phys 1990 18 : 299 304.
20. Grigsby PW, Perez CA, Kuten A et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992 22 : 905 11.
21. Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. Gynecol Oncol 1999 74 : 80 5.
22. Weiss E, Hirnle P, Arnold-Bofinger H et al. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol 1999 53 : 37 44.
23. Calvin DP, Conell PP, Rotmensch J et al. Surgery and postoperative radiotherapy in stage II endometrial carcinoma. Am J Clin Oncol 1999 22 : 338 43.